Luminal breast epithelial cells of BRCA1 or BRCA2 mutation carriers and noncarriers harbor common breast cancer copy number alterations | Marc J. Williams et al. | ResearchPod

Transcript: Luminal breast epithelial cells of BRCA1 or BRCA2 mutation carriers and noncarriers harbor common breast cancer copy number alterations

Alex: Welcome to another episode of ResearchPod. Today we're looking at a Nature Genetics study that substantially revises our picture of how breast cancer begins — not at the tumor stage, but potentially decades earlier, in tissue that looks completely normal under a microscope.

Sam: So the standard assumption — that genomic instability is a late-stage hallmark of established tumors — that's being challenged here?

Alex: Directly challenged. The central finding is that recurrent chromosomal copy number alterations are already present in histologically normal breast epithelium, and they mirror the large-scale genomic architecture of frank breast cancers. We're talking about gains and losses at specific loci — chromosome 1q gain, 16q loss — appearing in cells that a pathologist would sign off as benign.

Sam: Which raises an immediate question about detection. If standard histology misses these, how did the authors actually find them?

Alex: That's where the technical contribution sits. They used Direct Library Preparation Plus — DLP+ — to sequence close to 50,000 individual cells without clonal amplification. The key point is that bulk sequencing would average out the signal from rare aneuploid cells into background noise. Single-cell resolution is what makes the rare visible.

Sam: And how do they rule out sequencing artifact? Because rare events in single-cell data are notoriously hard to distinguish from technical noise.

Alex: The authors ran a direct comparison against an immortalized cell line where copy number alterations are uniform and well-characterized. Against that backdrop, the normal tissue showed something qualitatively different — highly recurrent, locus-specific patterns appearing across independent donors. Artifact would be stochastic. What they found was structured. That recurrence across donors is the load-bearing evidence here.

Sam: So the non-random, convergent nature of the alterations is doing the heavy lifting — it implies selective pressure rather than drift.

Alex: Exactly. When the same gain or loss appears independently in cells from different individuals, that's convergent evolution. It means luminal epithelial cells carrying those specific alterations have a fitness advantage, and natural selection is enriching for them — in normal tissue, years or decades before any clinical presentation.

Sam: You mentioned they used a hidden Markov model called SIGNALS. What work is that doing in the analysis?

Alex: SIGNALS is solving a specific inferential problem. When you see a clonal population of cells sharing the same copy number alteration, you can't immediately tell whether that's one ancestral event that expanded clonally, or multiple independent events that happened to produce the same alteration. Those two scenarios have very different implications for how early and how frequently these events arise. By phasing the alterations to specific parental alleles, SIGNALS can distinguish them. The authors used it to demonstrate that many of these events are genuinely independent — not the footprint of a single expanding clone.

Luminal breast epithelial cells of BRCA1 or BRCA2 mutation carriers and noncarriers harbor common breast cancer copy number alterations

Marc J. Williams, Michael U. J. Oliphant, Vinci Au, Cathy Liu, Caroline Baril, Ciara O’Flanagan, Daniel Lai, Sean Beatty, Michael Van Vliet, Jacky CH Yiu, Lauren O’Connor, Walter L. Goh, Alicia Pollaci, Adam C. Weiner, Diljot Grewal, Andrew McPherson, Klarisa Norton, McKenna Moore, Vikas Prabhakar, Shailesh Agarwal, Judy E. Garber, Deborah A. Dillon, Sohrab P. Shah, Joan S. Brugge, Samuel Aparicio

Sep 5, 2026·6:07·user_upload

Copy Number Alterations (CNAs)BRCA1/BRCA2 Mutation CarriersSingle-cell DNA sequencingConvergent EvolutionTumor InitiationSingle-cell whole-genome sequencing (scWGS)

Listen

6 min

Briefing

Research Question

While somatic mutations are known to accumulate in normal tissues, the role and timing of somatic copy number alterations (CNAs) in breast cancer initiation remain poorly understood. This study investigated the prevalence, distribution, and evolutionary timing of CNAs in morphologically normal breast epithelial cells from both BRCA1/BRCA2 germline mutation carriers and wild-type (WT) individuals.

Approach

Researchers performed single-cell whole-genome sequencing (scWGS) on 49,238 epithelial cells from 28 donors. They used the Direct Library Preparation+ (DLP+) protocol to identify copy number variations at megabase-scale resolution. The team sorted cells into luminal and basal populations and utilized allele-specific analysis to determine whether recurrent CNAs arose from single clonal expansions or independent mutational events.

Main Findings

Lineage Specificity: Aneuploidy is rare (3.25% overall) but significantly more prevalent in luminal epithelial cells (3.73%) than in basal myoepithelial cells (1.38%).
Recurrent Alterations: Specific CNAs—most notably gain of 1q and loss of 16q, 22q, and 10q—were recurrent across donors and restricted to the luminal lineage. These patterns closely resemble the copy number profiles of invasive breast cancers.
Convergent Evolution: Allele-specific analysis revealed that these recurrent CNAs arose through independent mutational events in different cells, suggesting convergent evolution where specific chromosomal changes provide a fitness advantage.
Extreme Aneuploidy: A small population of cells with extreme aneuploidy was identified in BRCA1/BRCA2 carriers. These cells often featured TP53 loss and BRCA1/BRCA2 loss of heterozygosity, resembling the genomes of advanced breast cancers.

Why It Matters

These findings demonstrate that the genomic landscape of breast cancer begins to take shape in normal, morphologically healthy luminal epithelium. By identifying these early, lineage-specific CNA precursors, the study provides a foundation for understanding the earliest stages of breast tumorigenesis and suggests that targeting these early progenitor clones could potentially serve as a strategy for cancer prevention or early monitoring.

Key Terms and Definitions

Copy Number Alterations (CNAs) — Genomic mutations involving the gain or loss of large segments of DNA or entire chromosomes, which alter gene dosage.
Luminal Cells — A specific subset of breast epithelial cells that serve as the primary compartment for the origin of most breast malignancies.
Aneuploidy — A state in which a cell contains an abnormal number of chromosomes or chromosome arms.
Loss of Heterozygosity (LOH) — A genetic event where one of the two parental alleles at a specific locus is lost, often exposing recessive mutations.
Convergent Evolution — An evolutionary process where independent cells or lineages acquire the same genetic alterations due to similar selective pressures or fitness advantages.

Luminal breast epithelial cells of BRCA1 or BRCA2 mutation carriers and noncarriers harbor common breast cancer copy number alterations: Research Paper Podcast